Canister Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is supplied as a controlled-atmosphere pharmaceutical intermediate in sealed cylindrical canisters rather than open-mouth drums. The product family is assigned internal grade codes for route-specific control: CAN-PG-API-TCGI-01 for direct compression tablet and capsule charging, CAN-PG-API-TCGI-02 for injectable formulation after downstream aseptic filtration or terminal sterilization, and CAN-PG-API-TCGI-03 for roller-compacted granule feed. These codes do not represent different active molecules; they identify separate physical grades of the same active substance. Solid oral grades are controlled for particle size, bulk and tapped density, loss on drying, and residual solvents. Injectable grades add bacterial endotoxin, bioburden, and sub-visible particulate controls relevant to parenteral compounding. The canister body for the injectable grade is fabricated from 316L stainless steel with an electropolished product-contact surface having surface roughness Ra ≤ 0.8 µm. Working volumes of 30 L, 60 L, and 120 L are available for solid oral material; the injectable canister is configured with a 0.2 µm hydrophobic vent filter and a tri-clamp discharge port. Release testing follows the applicable United States Pharmacopeia general chapters: USP <429> for laser diffraction particle size, USP <616> for bulk and tapped density, USP <731> for loss on drying, USP <467> for residual solvents, and USP <232>/<233> for elemental impurities with an ICH Q3D risk assessment. No international pharmacopeial monograph uses this proprietary descriptor; conformance is therefore established by the supplier certificate of analysis and route-specific user validation.

A representative specification framework is provided in Table 1. Acceptance criteria are route-dependent and must be recalculated for each active substance, dose, and dosage form. The values shown are control targets, not universal regulatory limits.

The tabulated parameters are not an assurance of blend uniformity or finished-product sterility. They define the incoming control envelope from which subsequent pharmaceutical processing must be validated.

What separates a canister-grade multi-route API from a conventional drum-sampled powder?

Conventional drum sampling introduces uncontrolled headspace and manual scooping. A fibre drum opened repeatedly in a non-controlled warehouse at 25 °C / 60% RH can raise loss on drying by 0.3–0.8% w/w over multiple shifts. By contrast, the canister keeps the powder under nitrogen overlay with oxygen headspace controlled to ≤ 2% v/v when specified. This difference has direct consequences for tablet and capsule manufacture. In a direct compression blend, water uptake alters particle adhesion and lubricant distribution. Weight variation on an instrumented rotary press running above 60 rpm can shift from a relative standard deviation near 1.2% to 2.5% when powder flow deteriorates. The canister discharge port typically incorporates a split butterfly valve or a disposable continuous-liner system, permitting gravity transfer into a closed intermediate bulk container without manual scooping. Open-drum transfer is less reproducible when batch records require complete discharge and minimal residual API loss. Table 2 summarises the operational differences.

Direct compression grade material is released with Hausner ratio 1.20–1.45 and Carr index 15–30% using USP <616>. These values are screening tools rather than a flow guarantee. A flow function coefficient obtained by Schulze ring shear testing at 3 kPa pre-shear should exceed 10 for reliable die fill on rotary tablet presses. If the as-received powder is finer than D50 45 µm, static adhesion to the canister wall and press hopper may produce low tablet weight at start-up. If D90 exceeds 250 µm, segregation in the feed frame becomes measurable, especially when press speed exceeds 80 rpm. In capsule filling, dosator-type machines require minimum tapped density above 0.45 g/mL for consistent plug formation. Tamping-pin systems are more tolerant of low density but still exhibit weight variation if Carr index exceeds 30%. These boundaries are not compound-specific and require actual measurement for each formulation.

When terminal sterilization is unavailable, injectable canister powder transfer moves under aseptic rather than sanitary boundary

An injectable canister grade is not a sterile API. It is a low-bioburden, low-endotoxin powder intended for reconstitution in Water for Injection and subsequent aseptic processing. The canister-to-solution transfer is performed in an ISO 7 buffer room with local ISO 5 protection or in a closed isolator. Once the powder is dissolved, the solution is sterile-filtered through a 0.22 µm sterilizing-grade membrane and filled into sterilized vials or ampoules. If the molecule tolerates moist-heat sterilization, terminal sterilization of the finished solution at 121 °C for 15 min is preferred; otherwise aseptic processing is required. Endotoxin limits are not fixed at an API level but are calculated from the maximum adult or paediatric dose using USP <85> K/M, where K is 5 EU/kg for the parenteral route. A fixed API acceptance criterion of 0.25 EU/mg is valid only when the maximum dose is defined; for high-dose parenterals above 20 mg/kg, the limit must be tightened accordingly. Sub-visible particulate matter is regulated on the finished product by USP <788> and Ph. Eur. 2.9.19. The API powder cannot carry a single compendial particulate limit, but particulate contamination from canister cleaning, valve friction, or filter shedding is controlled by component qualification and cleaning validation under FDA 21 CFR 211.67. Published data for the specific model CAN-PG-API-TCGI-02 in lyophilized parenteral products is limited; developers should qualify reconstitution time, filter capacity, and container-closure integrity with their own process.

Granule feed for roller compaction is discharged from the canister through a conical anti-segregation port into the feed hopper of a roller compactor. A typical dry granulation run uses roll force in the range 20–30 kN/cm, gap 1.5–2.5 mm, and screen 0.8 mm; these parameters are adjusted to produce a granule fraction with D50 200–400 µm. The controlled discharge of the canister contrasts with scooping from an open drum, where radial segregation creates a fines-rich top layer and a coarse bottom layer. Such stratification leads to granule hardness variation and downstream tablet capping. If the API is highly cohesive, the canister may be fitted with a low-speed rotary feeder and nitrogen purge, but the product is not an excipient and does not replace roller compaction when Carr index exceeds 30%.

Moisture permeation, valve leakage, and batch-to-batch mass flow

Residual moisture control is governed by the canister closure system rather than by passive storage alone. The sealing interface uses a silicone or PTFE gasket with water vapour transmission rate typically below 0.01 g/day at 38 °C / 90% RH; this value must be verified using supplier stability data for the specific gasket formulation. The 0.2 µm vent filter equalises pressure during discharge while blocking microbial ingress only when kept dry. If condensation forms in the vent line during cold-room storage, filter integrity may fail; the canister should not be moved directly from 2–8 °C storage into a humid manufacturing corridor without a pressure-equalisation procedure. Mass flow through the discharge valve is influenced by outlet diameter. A 50 mm outlet may be insufficient for cohesive powder with flow function coefficient below 5; a 100 mm or 150 mm split-valve outlet is preferred for granule and powder discharge into large blending containers. Batch-to-batch mass flow variation is monitored by recording discharge time through the canister valve. Variation exceeding ±15% from the qualified discharge time for a given port configuration indicates powder flow drift, bridging, or partial valve obstruction.

Residual moisture directly affects granule hardness in wet granulation and compact hardness in roller compaction. When loss on drying increases from 0.5% w/w to 1.0% w/w, granule friability can increase and tablet tensile strength can decrease because binder distribution is affected by surface moisture. For moisture-sensitive active substances, the canister interior may be treated with a dry nitrogen purge prior to sealing; an oxygen target ≤ 2% v/v and a water dew point below −40 °C are used as control limits. These limits are operational, not stability endpoints. They must be confirmed by real-time storage studies under the intended warehouse and transfer conditions.

Capsule filling with the solid oral canister grade is performed on dosator or tamping-pin encapsulation machines. The canister discharge port connects directly to the encapsulation hopper through a closed transfer sleeve. For low-dose capsules, blend uniformity is assessed by stratified sampling at the beginning, middle, and end of the encapsulation run; acceptance follows the relevant pharmacopeial blend uniformity chapter, typically with relative standard deviation ≤ 5.0% for individual content uniformity. If the API canister remains unopened until use, the moisture uptake during the encapsulation campaign is reduced compared with drum-sampled powder. However, the capsule shell itself requires storage at 20–25 °C and 35–65% RH to maintain brittleness control; the API canister condition does not override capsule shell storage requirements.

Usage of the injectable grade in oral liquid formulations is technically possible when the formulation is non-sterile. In that case, the endotoxin and particulate controls are not required at the same stringency as parenteral use, but the injectable grade can be used to reduce bioburden in high-risk oral liquids. The reverse substitution is not permitted: a solid oral canister grade must not be used for injectable formulation solely because the active substance is chemically identical. The solid oral canister grade is not released with the same endotoxin, bioburden, particulate, and transfer-interface controls that are required for parenteral processing. The difference is not a statement of chemical purity; it is a statement of route-specific contamination control.

The model designation CAN-PG-API-TCGI-03 for granule feed does not mean the API is pre-granulated. It indicates that the as-received powder has been sized and conditioned for roller compaction. If direct compression is attempted with the granule feed grade, flow may appear acceptable, but the larger particle size and lower compactibility can produce weak tablets because the grade is not optimised for direct compression. Conversely, the direct compression grade is not optimised for roller compaction because its particle size distribution may be too fine to form uniform ribbons. Each grade is therefore assigned to a specific unit operation and should not be interchanged without process revalidation.

For injectable grade canister cleaning, the canister interior is washed, rinsed, passivated, and dried after each use. Cleaning validation quantifies residual active substance, cleaning agent, and particulate burden. The acceptance limit for active residue is typically ≤ 10 ppm in the subsequent batch, calculated from the maximum safe carryover value. Surface roughness Ra ≤ 0.8 µm supports cleaning reproducibility but does not eliminate the need for visual inspection. The canister valve, gasket, and vent filter are wear components that must be inspected before each use. If the valve gasket shows cracking or sealing compression set, the canister should be refitted before powder charging. The canister is not rated for steam sterilisation in place unless the specific model documentation provides a validated sterilisation-in-place cycle. Published data for this exact canister configuration under saturated steam is limited; therefore sterilisation-in-place should not be assumed.

Batch release documentation includes certificate of analysis, grade code, canister identification, discharge port size, nitrogen overlay reading, and cleaning validation reference. The canister identification ties the powder to the specific cleaning cycle and weighing record. This differs from conventional drum release documentation, which often lacks an independent container closure integrity check. The canister vent filter integrity may be checked by water intrusion or bubble point method, depending on filter type. A typical 0.2 µm hydrophobic filter has a bubble point above 1.0 bar when wetted with water; the measured value is recorded on the canister release sheet. If the filter fails the bubble point or water intrusion limit, the canister is not accepted for injectable use.

Formulation developers using this product must establish three route-specific control boundaries. First, solid oral direct compression requires particle size, moisture, and flow characterisation as part of blend development. Second, injectable processing requires endotoxin, bioburden, and particulate qualifiers in addition to chemical purity. Third, granule feed requires roller compaction and sieve analysis to control ribbon density and granule size. These boundaries are not interchangeable across dosage forms without new process qualification. The canister closure system is a packaging and transfer interface, not a substitute for pharmaceutical process validation under FDA 21 CFR 211 and applicable ICH guidelines.